Further research found that the combination of MC-4 and everolimus can synergistically exert anticancer effects through AKT/PKM2 and mTOR to inhibit cancer growth and metastasis, which provides a theoretical basis for the combination of targeted therapy with glycolysis inhibitors [222]. Here, PKM is linked to cancer.